

Anti-IL-23 Reference Antibody (brazikumab)

Recombinant Antibody Catalog # APR10633

Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	Q9NPF7
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	20730

Additional Information

Target/Specificity	IL-23
Endotoxin Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information

	GRF
di by he JA le Pu se pr (P in ar	Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays ifferent roles in innate and adaptive immunity (PubMed: <u>11114383</u>). Released y antigen-presenting cells such as dendritic cells or macrophages, binds to a eterodimeric receptor complex composed of IL12RB1 and IL23R to activate AK2 and TYK2 which then phosphorylate the receptor to form a docking site eading to the phosphorylation of STAT3 and STAT4 (PubMed: <u>29287995</u> , ubMed: <u>32474165</u> , PubMed: <u>33606986</u>). This process leads to activation of everal pathways including p38 MAPK or NF-kappa-B and promotes the roduction of pro- inflammatory cytokines such as interleukin-17A/IL17A PubMed: <u>12023369</u>). In turn, participates in the early and effective intracellular bacterial clearance (PubMed: <u>32474165</u>). Promotes the expansion nd survival of T-helper 17 cells, a CD4-positive helper T-cell subset that roduces IL-17, as well as other IL-17-producing cells (PubMed: <u>17676044</u>).
	ecreted. Note=Secreted upon association with IL12B ecreted by activated dendritic and phagocytic cells and keratinocytes. Also

Images



Anti-IL-23 Reference Antibody (brazikumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-23 Reference Antibody (brazikumab)is more than 99.32% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.